A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
Bristol-Myers Squibb
Boehringer Ingelheim
National Cancer Institute (NCI)
National Cancer Institute (NCI)
OncoC4, Inc.
Revolution Medicines, Inc.
Seagen Inc.
National Institutes of Health Clinical Center (CC)
Erasca, Inc.
Novartis
GlaxoSmithKline
Incyte Corporation
Pfizer
Pfizer
Tomsk National Research Medical Center of the Russian Academy of Sciences
M.D. Anderson Cancer Center
Eisai Inc.
Erasca, Inc.
Genentech, Inc.
Poseida Therapeutics, Inc.
Astellas Pharma Inc
Seagen Inc.
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
AgonOx, Inc.
Peking University Cancer Hospital & Institute
Novartis
Amgen
Bristol-Myers Squibb
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
HiFiBiO Therapeutics
Enliven Therapeutics
AbbVie
Tesaro, Inc.
TORL Biotherapeutics, LLC
Sichuan Baili Pharmaceutical Co., Ltd.
Sichuan Baili Pharmaceutical Co., Ltd.
HUYABIO International, LLC.
HUYABIO International, LLC.
M.D. Anderson Cancer Center
Valo Therapeutics Oy
Exelixis
Toray Industries, Inc
DEKA Biosciences
AbbVie
University of California, Irvine
Amal Therapeutics
Carisma Therapeutics Inc
Exelixis